Clinical Catch-Up: January 18-22 | BioSpace
The Pharma Data
JANUARY 24, 2021
It inked a deal with the National Institute of Allergy and Infectious Diseases (NIAID) to launch a Phase I trial. National Institute of Allergy and Infectious Diseases (NIAID), of bamlanivimab (LY-CoV555) decreased the risk of COVID-19 among residents and staff of long-term care facilities, i.e., nursing homes.
52 
Let's personalize your content